CytomX Therapeutics Stock Forecast, Price & News

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CytomX Therapeutics in the last year. There are currently 1 sell rating, 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" CytomX Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CTMX, but not buy additional shares or sell existing shares.
View analyst ratings for CytomX Therapeutics or view top-rated stocks.

Wall Street analysts have given CytomX Therapeutics a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but CytomX Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

CytomX Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for CytomX Therapeutics.

CytomX Therapeutics, Inc. (NASDAQ:CTMX) issued its earnings results on Thursday, May, 6th. The biotechnology company reported ($0.26) EPS for the quarter, beating the Zacks' consensus estimate of ($0.29) by $0.03. CytomX Therapeutics had a negative net margin of 90.87% and a negative trailing twelve-month return on equity of 80.13%.
View CytomX Therapeutics' earnings history.

CytomX Therapeutics' stock was trading at $5.87 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CTMX stock has increased by 23.3% and is now trading at $7.24.
View which stocks have been most impacted by COVID-19.

5 analysts have issued 12 month target prices for CytomX Therapeutics' shares. Their forecasts range from $7.00 to $14.00. On average, they anticipate CytomX Therapeutics' stock price to reach $10.38 in the next year. This suggests a possible upside of 43.3% from the stock's current price.
View analysts' price targets for CytomX Therapeutics or view top-rated stocks among Wall Street analysts.

11 employees have rated CytomX Therapeutics CEO Sean A McCarthy on Glassdoor.com. Sean A McCarthy has an approval rating of 65% among CytomX Therapeutics' employees.

Some companies that are related to CytomX Therapeutics include Harmony Biosciences (HRMY), Amneal Pharmaceuticals (AMRX), Madrigal Pharmaceuticals (MDGL), Arcus Biosciences (RCUS), Zymeworks (ZYME), Protagonist Therapeutics (PTGX), Applied Molecular Transport (AMTI), Cerevel Therapeutics (CERE), uniQure (QURE), Supernus Pharmaceuticals (SUPN), PureTech Health (PRTC), Aurinia Pharmaceuticals (AUPH), Indivior (INVVY), Constellation Pharmaceuticals (CNST) and Y-mAbs Therapeutics (YMAB).
View all of CTMX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other CytomX Therapeutics investors own include Gilead Sciences (GILD), Exelixis (EXEL), AbbVie (ABBV), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), SCYNEXIS (SCYX), Bausch Health Companies (BHC), Bristol-Myers Squibb (BMY) and Dynavax Technologies (DVAX).

CytomX Therapeutics trades on the NASDAQ under the ticker symbol "CTMX."

CytomX Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Point72 Asset Management L.P. (9.74%), BlackRock Inc. (7.98%), RA Capital Management L.P. (5.38%), Victory Capital Management Inc. (4.26%), Perceptive Advisors LLC (3.31%) and Price T Rowe Associates Inc. MD (2.61%).
View institutional ownership trends for CytomX Therapeutics.

CTMX stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Perceptive Advisors LLC, D. E. Shaw & Co. Inc., Morgan Stanley, Man Group plc, Panagora Asset Management Inc., Credit Suisse AG, and Thrivent Financial for Lutherans.
View insider buying and selling activity for CytomX Therapeutics or view top insider-selling stocks.

CTMX stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., RA Capital Management L.P., BlackRock Inc., Price T Rowe Associates Inc. MD, Platinum Investment Management Ltd., Victory Capital Management Inc., Geode Capital Management LLC, and Janus Henderson Group PLC.
View insider buying and selling activity for CytomX Therapeutics or or view top insider-buying stocks.

Shares of CTMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CTMX stock can currently be purchased for approximately $7.24.

CytomX Therapeutics has a market capitalization of $470.68 million and generates $100.36 million in revenue each year. The biotechnology company earns $-32,880,000.00 in net income (profit) each year or ($0.71) on an earnings per share basis.

CytomX Therapeutics employs 144 workers across the globe.

The official website for CytomX Therapeutics is www.cytomx.com.

CytomX Therapeutics is headquartered at 151 OYSTER POINT BLVD.SUITE 400, SOUTH SAN FRANCISCO CA, 94080.

CytomX Therapeutics' mailing address is 151 OYSTER POINT BLVD.SUITE 400, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-515-3185 or via email at [email protected]